Looking at CEPH's pipeline, I think TEVA would consider cinquil as the best longer duration asset cause of their strong involvement in the respiratory arena and the potential for this drug. No doubt they see good oportunity in the stem cell area as they have already established a JV with a loacal company in the area ( http://www.gamida-cell.com/press_item.asp?ID=48 ). So far, interim data from phase IIa trial in CHF for Mesoblat's revascor were clean (safety) and stat-sig better than control in serious adverse cardiac events.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.